Overview

A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study

Status:
Completed

Trial end date:
2018-05-09

Target enrollment:

Participant gender:

Summary

PC786 is a new medicine being developed for treatment of respiratory syncytial virus. The main purpose of this study is to evaluate the antiviral activity of PC786 in healthy adults infected with RSV virus in a viral challenge study.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pulmocide Ltd

Treatments:

PC-786